Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plavix Patent Upheld By Court, Blocking Generic Clopidogrel

This article was originally published in The Pink Sheet Daily

Executive Summary

Apotex says it will immediately appeal the decision in favor of Sanofi-Aventis/Bristol-Myers Squibb.

You may also be interested in...



Stop The Bleeding: Sanofi-Aventis Looks To Sell A Generic Plavix In Europe

If a bioequivalent version of the clot buster launches in France, Sanofi is preparing to roll out its own generic version of clopidogrel.

Stop The Bleeding: Sanofi-Aventis Looks To Sell A Generic Plavix In Europe

If a bioequivalent version of the clot buster launches in France, Sanofi is preparing to roll out its own generic version of clopidogrel.

Apotex Seeks To Maintain 156 Days Of Exclusivity For Generic Plavix

Apotex petitions FDA to stay action on other clopidogrel ANDAs, as Dr. Reddy’s gets into position for a generic launch.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel